Posts

MBRX Pipeline

IMPORTANT DISCLAIMER This post is for informational and educational purposes only. It is NOT financial, investment, or trading advice. I am not a registered investment advisor, broker, or financial professional. Nothing here constitutes a recommendation to buy, sell, or hold any security, including MBRX. Investing in stocks, especially small-cap biotechs, involves a high degree of risk and can result in the complete loss of your investment. Past performance or recent news is no guarantee of future results. Always do your own research (DYOR), consider your risk tolerance, and consult a licensed financial advisor before making any investment decisions. Trade at your own risk—I will not be held liable for any losses. MBRX Breakout Alert: Moleculin Biotech's MIRACLE Trial Data Sparks 10%+ Surge – Should You Jump In? February 18, 2026 | By Shane Shipman (@shaneman007) Hey everyone, if you're like me—scanning for those explosive small-cap biote...

Stock Price History Doesn't Match Company Visibility

Next Up After RIVN: 4 Stocks Poised for a Potential Breakout in 2026 Hunting for bargains where the price has tanked despite better fundamentals, high short interest, and catalysts on the horizon. (February 2026 update) Important Disclaimers – Read This First This is NOT financial advice. I'm sharing my observations and research as of mid-February 2026, based on public data, analyst notes, and market chatter. Stock markets are unpredictable, especially with high-short-interest names that can swing wildly on news, earnings, or sentiment shifts. These ideas involve significant risk: volatility, potential dilution, execution failures, or prolonged "irrational" pricing. High short interest can fuel squeezes... or lead to brutal squeezes in the wrong direction if catalysts disappoint. Do your own due diligence. Past performance (like RIVN's recent run) doesn't guarantee future results. I may hold or trade positions in these or related stocks—al...

Hard Rebound? Keeping an OPEN mind

Nasdaq Reverse Split + Delisting Setups (February 18, 2026) High-risk distress plays are stacking up again. As of February 18, 2026, several Nasdaq-listed companies are showing overlapping signals: Recent reverse splits Sub-$1 bid price violations Delisting determinations Ineligibility for grace periods Appeal/hearing uncertainty This type of multi-factor distress setup closely resembles the pre-run profile seen in OPEN prior to its July bounce — where sub-$1 pressure, reverse split filings, and delisting risk created a volatility catalyst. Strongest Multi-Criteria Overlap AREB – American Rebel Holdings Ticker: AREB TradingView Chart: View AREB on TradingView 1-for-20 reverse split effective February 2, 2026 Nasdaq delisting determination issued February 4, 2026 Sub-$1 bid price for 30+ days Multiple prior reverse splits (extreme cumulative ratio since late 2024) Initially no appeal — then appeal filed February 11 This is a hig...

MAMO Massimo

MAMO Turnaround Potential: Speculative Recovery or Early Rebound? Small-cap turnarounds can be some of the most explosive opportunities in the market — but they can also be some of the riskiest. Recently, investors have been asking whether Massimo Group (NASDAQ: MAMO) is showing signs of a legitimate turnaround or simply experiencing a temporary bounce. Recent Signs of Improvement Massimo Group, a powersports and electric utility vehicle manufacturer, has recently reported a return to profitability after prior losses. Improved gross margins and cost controls appear to be contributing to better bottom-line performance. A return to positive net income is often the first major milestone in a turnaround story. However, sustainability matters far more than a single profitable quarter. Strategic Shifts The company has made several strategic adjustments, including: Nearshoring elements of its supply chain to reduce risk and improve margins Expanding e-commerce and dealer dist...

February 17th Eyes On The Market

On the Cusp: High-Probability Momentum Plays for the Week Ahead (Feb 2026) Spotting asymmetric setups in pennies, biotech shells, and AI/BTC infra—straight from momentum scans and trader buzz. These are volatile, high-risk ideas only. IMPORTANT DISCLAIMER: This post is for informational and educational purposes ONLY. It is NOT financial advice, investment recommendation, or solicitation to buy/sell any security. Trading stocks (especially low-float pennies and sub-$1 names) involves SUBSTANTIAL RISK of loss and can result in the loss of your entire investment. Past performance is NOT indicative of future results. Markets are unpredictable—catalysts can fail, dilution can occur, pumps/dumps happen. Always Do Your Own Research (DYOR), use proper risk management (stops, position sizing), and consult a licensed financial advisor before trading. I am not a registered advisor. Trade at your own risk. Tier 1: Highest-Probability Imminent Movers These have fr...

A Gambler's Market

February 2026: The Gainz Watchlist FEBRUARY 2026 WATCHLIST Analyzing Lower Risk / High Reward Scenarios As we move through February 2026, the market is presenting several unique "asymmetric" opportunities. Below is a breakdown of the tickers currently on my radar, ranging from merger arbitrage to commodity trends. $SGN Merger Play Thesis: Anticipating a merger with BlockchAIn Digital in March 2026. Currently watching for a .225/.23 entry point. Risk Level: MEDIUM (Time-bound execution risk). $LFS Insider Scalp Thesis: Japanese firm with high insider holding (52.89%). Looking for a confirmed break above $3.25 resistance. Risk Level: LOWER (Strong internal ownership). $ISPC AI Marketplace Thesis: Post-Milestone 2 ph...

HBAR I'm Down Bad So Far.

HBAR Strategy 2026: Averaging Down Navigating the Deep Red: Is Averaging Down on Hedera (HBAR) a Smart Play in 2026? Disclaimer: This article is for informational purposes only and should not be considered financial advice. Cryptocurrency investments are highly volatile and speculative. Always conduct your own research and consult with a financial professional before making any investment decisions. It’s a familiar, gut-wrenching feeling for many crypto investors: watching a promising asset plummet, leaving your portfolio deep in the red. If you’re down 60% on your Hedera (HBAR) position, you’re not alone. Many who entered during the 2024 hype, drawn by its "enterprise-grade" potential, are now facing a significant loss. The big question then becomes: Is this the time to average down, or is it throwing good money after bad? As of mid-February 2026, there are compelling arguments emerging that suggest the tide migh...